FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667750> ?p ?o ?g. }

• W4385667750 endingPage "e5816560" @default.
• W4385667750 startingPage "e5816560" @default.
• W4385667750 abstract "Background: The proper administration of TKIs after Allo-SCT in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) remains controversial and the TKI approach (prophylactic, pre-emptive or salvage) is still heterogeneous through transplant centers. In this context, very little is known about the efficacy and safety of third-generation TKIs Aims: Here we present the preliminary results of the ongoing multicentre study to analyse efficacy and safety profile of therapy with ponatinib (PONA) after Allo-SCT to prevent Ph+ ALL cytological relapse. Methods: We report the analysis of the first 48 included patients (pts) with Ph+ ALL (median age 49 years; range 20-70) who received PONA after their Allo-SCT (donors: 24 MUD, 11 siblings HLA Id and 9 Haplo and 4CB). All 48 pts received Allo-SCT while in complete cytological remission (cCR) and 26 pts (54%) had positive minimal residual disease (MRD+) before Allo-SCT. PONA was administered after Allo-SCT prophylactically (starting with MRD neg) in 26 pts or pre-emptively (starting with MRD positivity post-SCT and without hematological relapse) in 22 pts Results: The 26 pts treated prophylactically with PONA started treatment earlier, at a median of 4,3 months (range 1,5-6) after Allo-SCT, than the 22 pts treated pre-emptively, who started PONA at a median of 7,4 months (range 2-63) after Allo-SCT (p=0,01). The median starting dose of PONA was 30 mg/day (range 15-45). Reduction of the initial dose was required in 15/48 (31%) of cases (mainly in those receiving an initial dose of 45 mg/day), but a permanent discontinuation of PONA, due to toxicity, was required in only 5/48 pts (10,4%). No deaths due to PONA-related adverse events were reported. The mean and median follow-up time after Allo-SCT was 40±26 and 34 months (range 7,7-118), respectively. At last follow-up, the median duration of PONA therapy was 22 months (range 2-100). Detailed data on the safety profile of PONA were collected. In addition to PONA, 10 pts received donor lymphocyte infusions. The 5-year OS and RFS after Allo-SCT of all 48 pts were 92% and 71%, respectively (Figure 1a and 1b). The 5-year RFS after Allo-SCT of pts who received PONA as prophylaxis was 95% and it was 57% for those who received PONA pre-emptively (log-rank p=0,02). Summary/Conclusion: Preliminary data obtained from this analysis, in a homogeneous population of Ph+ ALL undergoing Allo-SCT while in CcR, although with the caution of the retrospective data, support the efficacy and safety of PONA as a maintenance strategy after Allo-SCT, resulting in a high probability of OS and DFS and in a low rate of discontinuation due to PONA-related toxicity. However, in the majority of cases where a daily dose of 45 mg was started a dose reduction to 30-15 mg/day was required, which seems to be the appropriate dose to balance efficacy and tolerability.Keywords: allo BMT, Ph+ ALL, Acute lymphoblastic leukemia" @default.
• W4385667750 created "2023-08-09" @default.
• W4385667750 creator A5003619706 @default.
• W4385667750 creator A5011666578 @default.
• W4385667750 creator A5019480794 @default.
• W4385667750 creator A5022330993 @default.
• W4385667750 creator A5030793344 @default.
• W4385667750 creator A5036399118 @default.
• W4385667750 creator A5041181079 @default.
• W4385667750 creator A5042424261 @default.
• W4385667750 creator A5044096443 @default.
• W4385667750 creator A5044624520 @default.
• W4385667750 creator A5054730102 @default.
• W4385667750 creator A5062819489 @default.
• W4385667750 creator A5073776156 @default.
• W4385667750 creator A5075520151 @default.
• W4385667750 creator A5086540907 @default.
• W4385667750 date "2023-08-01" @default.
• W4385667750 modified "2023-09-27" @default.
• W4385667750 title "P371: PONATINIB AS A PROPHYLACTIC OR PRE-EMPTIVE STRATEGY TO PREVENT CYTOLOGICAL RELAPSE AFTER ALLO-SCT IN PATIENTS WITH PH POS ALL TRANSPLANTED IN COMPLETE CYTOLOGICAL REMISSION" @default.
• W4385667750 doi "https://doi.org/10.1097/01.hs9.0000968396.58165.60" @default.
• W4385667750 hasPublicationYear "2023" @default.
• W4385667750 type Work @default.
• W4385667750 citedByCount "0" @default.
• W4385667750 crossrefType "journal-article" @default.
• W4385667750 hasAuthorship W4385667750A5003619706 @default.
• W4385667750 hasAuthorship W4385667750A5011666578 @default.
• W4385667750 hasAuthorship W4385667750A5019480794 @default.
• W4385667750 hasAuthorship W4385667750A5022330993 @default.
• W4385667750 hasAuthorship W4385667750A5030793344 @default.
• W4385667750 hasAuthorship W4385667750A5036399118 @default.
• W4385667750 hasAuthorship W4385667750A5041181079 @default.
• W4385667750 hasAuthorship W4385667750A5042424261 @default.
• W4385667750 hasAuthorship W4385667750A5044096443 @default.
• W4385667750 hasAuthorship W4385667750A5044624520 @default.
• W4385667750 hasAuthorship W4385667750A5054730102 @default.
• W4385667750 hasAuthorship W4385667750A5062819489 @default.
• W4385667750 hasAuthorship W4385667750A5073776156 @default.
• W4385667750 hasAuthorship W4385667750A5075520151 @default.
• W4385667750 hasAuthorship W4385667750A5086540907 @default.
• W4385667750 hasBestOaLocation W43856677501 @default.
• W4385667750 hasConcept C126322002 @default.
• W4385667750 hasConcept C141071460 @default.
• W4385667750 hasConcept C151730666 @default.
• W4385667750 hasConcept C187212893 @default.
• W4385667750 hasConcept C2776694085 @default.
• W4385667750 hasConcept C2779343474 @default.
• W4385667750 hasConcept C3018657049 @default.
• W4385667750 hasConcept C71924100 @default.
• W4385667750 hasConcept C86803240 @default.
• W4385667750 hasConcept C90924648 @default.
• W4385667750 hasConceptScore W4385667750C126322002 @default.
• W4385667750 hasConceptScore W4385667750C141071460 @default.
• W4385667750 hasConceptScore W4385667750C151730666 @default.
• W4385667750 hasConceptScore W4385667750C187212893 @default.
• W4385667750 hasConceptScore W4385667750C2776694085 @default.
• W4385667750 hasConceptScore W4385667750C2779343474 @default.
• W4385667750 hasConceptScore W4385667750C3018657049 @default.
• W4385667750 hasConceptScore W4385667750C71924100 @default.
• W4385667750 hasConceptScore W4385667750C86803240 @default.
• W4385667750 hasConceptScore W4385667750C90924648 @default.
• W4385667750 hasIssue "S3" @default.
• W4385667750 hasLocation W43856677501 @default.
• W4385667750 hasLocation W43856677502 @default.
• W4385667750 hasOpenAccess W4385667750 @default.
• W4385667750 hasPrimaryLocation W43856677501 @default.
• W4385667750 hasRelatedWork W113810927 @default.
• W4385667750 hasRelatedWork W1586374228 @default.
• W4385667750 hasRelatedWork W2003938723 @default.
• W4385667750 hasRelatedWork W2047967234 @default.
• W4385667750 hasRelatedWork W2118496982 @default.
• W4385667750 hasRelatedWork W2364998975 @default.
• W4385667750 hasRelatedWork W2369162477 @default.
• W4385667750 hasRelatedWork W2439875401 @default.
• W4385667750 hasRelatedWork W4238867864 @default.
• W4385667750 hasRelatedWork W2525756941 @default.
• W4385667750 hasVolume "7" @default.
• W4385667750 isParatext "false" @default.
• W4385667750 isRetracted "false" @default.
• W4385667750 workType "article" @default.